A Phase II Trial of Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2016 Status changed from not yet recruiting to recruiting.
- 20 May 2016 New trial record